Business Wire

  1. insitro Partners With Lilly To Build First-In-Kind Machine Learning Models To Advance Small Molecule Drug Discovery 9/9/2025

    insitro, a pioneer in machine learning for drug discovery and development, today announced a new collaboration with Eli Lilly and Company (Lilly) to develop advanced machine learning models that can accurately predict key pharmacological properties of small molecules, including their behavior in vivo.

  2. Avenzo Therapeutics Announces FDA Clearance Of Investigational New Drug Application For AVZO-103, A Potential Best-In-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate 9/2/2025

    Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-103 (formerly VAC-103), a potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate (ADC).

  3. Enlaza Therapeutics Announces Strategic Collaboration With Vertex Pharmaceuticals To Develop War-Lock Drug Conjugates And T-Cell Engagers For Improved Conditioning And Certain Autoimmune Diseases 9/2/2025

    Enlaza Therapeutics (“Enlaza” or the “Company”), the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals (“Vertex”) to utilize Enlaza’s proprietary War-Lock technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.

  4. iXCells Biotechnologies Selected To Perform The First Pilot In Patient-Led ALS Precision Medicine Effort 8/26/2025

    Mosaic Neuroscience and iXCells Biotechnologies USA, Inc. (“iXCells”) today announced a groundbreaking pilot project aimed at making it easier to develop precision drugs for ALS, a notoriously complex and deadly disease.

  5. Tivic Receives Two Investigational New Drug Applications For Entolimod For The Treatment Of Acute Radiation Syndrome (ARS) And Advanced Cancers 8/20/2025

    Tivic Health Systems, Inc., a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod.

  6. N-Power Medicine Launches Industry's First Prospective External Control Arm Platform To Dramatically Accelerate Oncology Drug Development And Reduce Reliance On Randomization 8/19/2025

    N-Power Medicine, a company reimagining oncology drug development, today announced the launch of the industry’s first Prospective External Control Arm (ProECA) platform for pharmaceutical and biotechnology partners.

  7. VASTHERA Receives U.S. FDA Clearance To Initiate Phase 1 Clinical Trial Of Pulmonary Arterial Hypertension Drug Candidate, VTB-10 8/19/2025

    On August 6, 2025, VASTHERA Co., Ltd. announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for VTB-10, its drug candidate for pulmonary arterial hypertension (PAH), a rare, life-threatening disease marked by elevated blood pressure in the lung arteries.

  8. BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering Of Groundbreaking Software With Customizable Interface For AI-Driven Drug Discovery 6/10/2024

    ImmunoPrecise Antibodies Ltd. (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces the commercial release of LENSai API, hereafter referred to as the ‘software’, by its subsidiary, BioStrand. This advanced AI-driven software solution is available immediately.

  9. Every Cure Deploys BioPhy's Artificial Intelligence Platform To Accelerate Its Mission Of Repurposing Drugs For Untreated Diseases 4/30/2024

    BioPhy, an innovative AI drug development company, today announced a partnership with Every Cure, a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.

  10. X-Chem Acquires Glamorous AI — Immediately Creating A Leader In DEL-Powered AI Solutions 10/28/2021

    X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of Glamorous AI, a leader in artificial intelligence (AI) solutions for drug discovery.